poisar

Stocks · News reference

Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M

Aug 14, 2026, 11:22 AMBenzinga Newsdesk

Adlai Nortye (NASDAQ:ANL) reported quarterly losses of $(0.04) per share. This is a 78.95 percent increase over losses of $(0.19) per share from the same period last year. The company reported $13.056 million in sales

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ANL
Source
benzinga
Observed
Aug 14, 2026, 11:22 AM
Checked
Aug 14, 2026, 11:22 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 3, 2026, 11:04 AMBenzinga Newsdesk

    Adlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I Clinical Trial Evaluating AN4035 For Treatment Of CEACAM5-Enriched RAS-Addicted Solid Tumors

    First-in-class pan-RAS(ON) ADC is cleared for clinical developmentDesigned to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.IND submissions to U.S. FDA and China NMPA are in

    Read original at benzinga
    ANL